Cardiology journal · 2026
Adenosine and ATP differentially control osteogenic gene expression patterns in a cardiac valve cell line.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Borkowski Tomasz, Płoska Agata, Smoleński Ryszard T, Khalpey Zain, Runyan Raymond B, Bartoszewski Rafał, Jaguszewski Miłosz, Kalinowski Leszek
Аннотация
INTRODUCTION: Calcific aortic valve disease (CAVD) involves the osteogenic transition of valve interstitial cells (VICs) and is influenced by purinergic signaling. ATP is considered pro-calcific, whereas adenosine (Ado) has been reported as anti- or pro-calcific. Extracellular conversion of ATP to Ado by ecto-enzymes (including ecto-5'-nucleotidase, CD73) may shape receptor signaling in VICs.
MATERIAL AND METHODS: We quantified osteogenic and apoptotic markers in the murine valve-like cell line tsA58-AVM under osteogenic conditions after treatment with ATP or Ado, selective Adora1/Adora2A agonists, and/or CD73.
RESULTS: Runt-related transcription factor 2, isoform II (Runx2-II) expression decreased by 31% and 17% after 16 hours of exposure to 0.35 μM and 3.5 μM Ado, respectively. Adora1 activation (MeCCPA, 0.1 μM) reduced Runx2-II by 49-57% on days 1-5, and Adora2A activation (PSB0777, 1 μM) reduced Runx2-II by 17-63% at days 1-5. Repeated ATP addition (100 μM) increased osteopontin (SPP1) by 7.7- and 3.3-fold and osteocalcin (BGLAP) by 14.4- and 4.0-fold on days 5 and 12, respectively; cotreatment with CD73 (0.1 ng/μL) reduced or normalized these changes. ATP also doubled the Bcl-2- associated X protein (Bax) to B-cell lymphoma 2 protein (BCL2) ratio, an effect that was prevented by CD73.
CONCLUSIONS: Purinergic ligands and receptors directly regulate VIC osteogenic differentiation and apoptosis in vitro without exogenous inflammatory stimulation. Modulation of the ATP-Ado axis may represent a therapeutic target to slow CAVD progression.
MATERIAL AND METHODS: We quantified osteogenic and apoptotic markers in the murine valve-like cell line tsA58-AVM under osteogenic conditions after treatment with ATP or Ado, selective Adora1/Adora2A agonists, and/or CD73.
RESULTS: Runt-related transcription factor 2, isoform II (Runx2-II) expression decreased by 31% and 17% after 16 hours of exposure to 0.35 μM and 3.5 μM Ado, respectively. Adora1 activation (MeCCPA, 0.1 μM) reduced Runx2-II by 49-57% on days 1-5, and Adora2A activation (PSB0777, 1 μM) reduced Runx2-II by 17-63% at days 1-5. Repeated ATP addition (100 μM) increased osteopontin (SPP1) by 7.7- and 3.3-fold and osteocalcin (BGLAP) by 14.4- and 4.0-fold on days 5 and 12, respectively; cotreatment with CD73 (0.1 ng/μL) reduced or normalized these changes. ATP also doubled the Bcl-2- associated X protein (Bax) to B-cell lymphoma 2 protein (BCL2) ratio, an effect that was prevented by CD73.
CONCLUSIONS: Purinergic ligands and receptors directly regulate VIC osteogenic differentiation and apoptosis in vitro without exogenous inflammatory stimulation. Modulation of the ATP-Ado axis may represent a therapeutic target to slow CAVD progression.